Astorg’s Transformative Acquisition in the ART Sector
Astorg, a prominent private equity firm with a pan-European focus, has recently completed a significant strategic move by taking Hamilton Thorne private while simultaneously acquiring Cook Medical's Reproductive Health business. This dynamic acquisition positions Astorg to create a robust global player in assisted reproductive technology (ART).
Combining Forces for a Broader Reach
The integration of Hamilton Thorne's cutting-edge ART portfolio, which includes a wide array of precision instruments, software, and consumables, with Cook Medical's renowned ART consumables and equipment marks a pivotal moment for the fertility industry. The aim is to enhance the accessibility and outcomes of fertility treatments across the globe, serving customers in over 115 countries.
A New Era for the Combined Company
Astorg's vision is to leverage the strengths of both entities, ultimately forming an innovative global ART MedTech company. As part of this integration, a new brand identity for the combined business is slated for launch in 2025, which will reflect their unified commitment to improving fertility outcomes and supporting families on their fertility journeys.
Leadership Appointments for Future Growth
To guide this new entity through its next growth phase, Astorg has appointed a dedicated management team. Wil Boren has taken on the role of Chief Executive Officer (CEO), bringing with him an extensive background in the MedTech field. His prior experience includes leading Paragon Medical, where he made remarkable contributions to operational excellence and revenue growth.
Additionally, Jimmy DeStephens has been appointed as Chief Financial Officer (CFO) and Chief Operating Officer (COO). With over 20 years of experience in finance and operations within the MedTech sector, Jimmy is well-equipped to drive the combined organization forward.
Commentary from the Leadership Team
Olivier Lieven, Managing Director at Astorg, expressed his enthusiasm regarding the merger: “By combining forces, we are creating a unique, global ART business that is ideally positioned to tackle rising fertility challenges. Our aim is to provide unparalleled support to fertility professionals and families alike.”
This sentiment was echoed by Wil Boren, who noted the importance of collaboration between both teams to capitalize on their combined resources and expertise in the pursuit of improved fertility treatments worldwide.
A Strong Investment in Healthcare
Astorg has established itself as a key player in the healthcare sector, maintaining over €6.5 billion in investments within this space. Their portfolio includes notable stakeholders in B2B healthcare across Europe and the U.S., and this latest investment will integrate perfectly into Astorg VIII's portfolio.
As they embark on this new chapter, Astorg and the combined entity of Hamilton Thorne and Cook Medical RH look forward to redefining the standards in ART, bringing innovations that enhance service quality and patient care.
Frequently Asked Questions
What prompted Astorg’s acquisition of Hamilton Thorne and Cook Medical RH?
The acquisition aims to create a global leader in ART, addressing rising fertility challenges and enhancing product offerings.
Who are the key figures in the newly combined organization?
Wil Boren has been appointed as CEO, while Jimmy DeStephens serves as CFO and COO, both bringing extensive MedTech experience.
What is the expected outcome of this merger for the ART sector?
The merger is anticipated to provide improved access and outcomes for fertility treatments to clinics globally.
When will the new brand identity be introduced?
A new brand identity for the combined business is set to be launched in 2025.
What is Astorg's focus within the healthcare sector?
Astorg focuses on investing in leading B2B healthcare companies in Europe and the U.S., specializing in enhancing quality and innovation in the industry.
